Tony Wood, GSK CSO

‘Un­like­ly to trans­form pa­tient care’: GSK punts top late-stage drug af­ter PhI­II da­ta dis­ap­point

GSK has reached the end of the road with otil­imab, once hailed as a top prospect for rheuma­toid arthri­tis, af­ter a trio of Phase III tri­als yield­ed dis­ap­point­ing re­sults.

For­mer R&D chief Hal Bar­ron forged ahead with the late-stage en­deav­ors for otil­imab de­spite it flunk­ing a Phase II tri­al. While two of the three tri­als met their pri­ma­ry end­points, GSK says look­ing at the da­ta so far, “the ef­fi­ca­cy demon­strat­ed is un­like­ly to trans­form pa­tient care for this dif­fi­cult-to-treat pa­tient pop­u­la­tion.” As a re­sult, it is scrap­ping plans for reg­u­la­to­ry sub­mis­sions.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.